Skip to main content

Generics

  • Leveraging global strategy to help independents navigate macro trends in health care, business

  • Prasco to distribute Teva's generic of Adderall XR capsules

    CINCINNATI -- Prasco Laboratories has entered into agreements with Teva and Shire to acquire the rights to distribute the generic version of Adderall XR Extended Release Capsules. 

    As a result of this acquisition, Prasco will market an AG version of Adderall XR Capsules, CII in the United States that is therapeutically equivalent and substitutable for prescriptions written for Adderall XR, a CNS stimulant that is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

  • Mylan launches generic Avodart capsules

    HERTFORDSHIRE, England and PITTSBURGH -- Mylan announced Monday that it has launched Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart Capsules, in the U.S.

  • Senators, U.S. Rep introduce bill to shorten length of biologics exclusivity
    WASHINGTON — U.S. Rep. Jan Schakowsky and Sens. Sherrod Brown and John McCain on Thursday introduced a piece of legislation aimed at shortening the period of exclusivity for brand-name biologics products. The Price Relief, Innovation and Competition for Essential Drugs (PRICED) Act would amend the Public Health Service act to change the exclusivity period from 12 years to seven years. 
     

  • Pharmasave pharmacists trained in medication therapy management

    VANCOUVER, B.C. -- Pharmasave announced that its pharmacists have been trained to be leaders in providing medication therapy management programs.

    This includes reviewing medications for appropriateness, identifying potential problems such as drug interactions, alternative therapies and contraindications and patient counselling on appropriate use. 

  • Teva intros generic Entocort EC
    NORTH WALES, Penn. — Teva Pharmaceuticals on Thursday announced the introduction of its generic of Entocort EC (budesonide) enteric coated 3-mg capsules. The drug is indicated to treat mild to moderate active and in remission Crohn’s disease in the ileum and/or ascending colon. 
     

  • Study: Diabetes drug treats liver disease in Type 2, prediabetes patients
    PHILADELPHIA — A new study whose results were published online in the Annals of Internal Medicine has found promise for the treatment of the fatty liver disease nonalcoholic steatohepatitis (NASH) in patients with prediabetes and Type 2 diabetes. NASH currently has no FDA-approved treatment. 
     

  • Congress calls on CMS to finalize DIR guidance

    ALEXANDRIA, Va. - As many as 16 United States Senators and 30 members of the House of Representatives recently wrote to the Centers for Medicare & Medicaid Services, urging the agency to finalize its proposed guidance on how Medicare prescription drug plan sponsors report pharmacy price concessions, often referred to as direct and indirect remuneration (DIR) fees, to provide more accurate information to beneficiaries, pharmacies and the federal government.

X
This ad will auto-close in 10 seconds